Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01936649 · ClinicalTrials.gov registry record · Phase 4
Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.
A Phase 4 study of Heart Failure (HF) and Ventricular Dysfunction, Left, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 4
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT01936649 is a Phase 4 study of Heart Failure (HF) and Ventricular Dysfunction, Left that has completed, run by GE Healthcare. The registered enrollment target is 63 participants, below the 157-participant average among 3 other Heart Failure (HF) trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01936649, a Phase 4 study of Heart Failure (HF) and Ventricular Dysfunction, Left, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of the study was to assess the reproducibility of quantitative measurements of myocardial uptake of Iobenguane I 123 on planar and single photon emission computed tomography (SPECT) imaging following intravenous (i.v.) administration of AdreView. Efficacy was assessed based upon the absolute differences between quantitative analyses of imaging data on 2 scans performed 5 to 14 days apart.
Conditions Studied
Interventions
- DRUG AdreView (Iobenguane I 123 Injection)
Study Locations (1)
New Jersey
- GE Healthcare - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01936649
The ClinicalTrials.gov registry entry for NCT01936649 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 157-participant average among 3 other Heart Failure (HF) trials with a reported enrollment target (60% lower). The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Heart Failure (HF) appearing as the primary indexed condition, and to 1 intervention - of which AdreView (Iobenguane I 123 Injection) is the first listed.
NCT01936649 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT01936649 about?
NCT01936649 is a clinical study titled "Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.". The aim of the study was to assess the reproducibility of quantitative measurements of myocardial uptake of Iobenguane I 123 on planar and single photon emission computed tomography (SPECT) imaging following intravenous (i.v.) administration of AdreView. Efficacy was assessed based upon the absolute...
What is the current status of trial NCT01936649?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 63 participants. The study started on 2013-08. Estimated completion is 2014-02.
What conditions does trial NCT01936649 study?
This clinical trial studies the following conditions: Heart Failure (HF), Ventricular Dysfunction, Left.
What interventions are being tested in trial NCT01936649?
The interventions under investigation include: AdreView (Iobenguane I 123 Injection) (DRUG).
Who is sponsoring clinical trial NCT01936649?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01936649 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure (HF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
COMPLETED · Phase 4
-
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
RECRUITING · NA
-
REsynchronization Comparison In LBBB and Normal or Mildly Reduced VENTricular Function With CRT (REINVENT-CRT)
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.